RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In May 2023, the United States Food and Drug Administration approved a Pfizer©-sponsored (Pfizer, New York, NY, USA) bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) RSV vaccine (AbrysvoTM [Pfizer]) for use during pregnancy to prevent neonatal/infant RSV infection. In February of 2022, trials sponsored by GSK© (Brentford, England, UK) on a similar RSVpreF vaccine were halted because of the identification of a safety signal related to preterm births. As these vaccines use identical pre-fusion F-protein technology, we sought to synthesize the existing data on their effectiveness and safety. We identified all randomized controlled trials and used RevMan 5.4.1 (The Cochrane Collaboration, England, UK) to perform the analysis with 95% confidence intervals and risk ratios (RRs). We found many maternal side effects were more prevalent in the RSVpreF group, with more local reactions, blood disorders, fatigue, joint pain, cardiac disorders, headache, fever, gastrointestinal disorders and pregnancy complications. The vaccinated group demonstrated significant reductions in RSV-lower respiratory tract cases (RR, 0.44 [0.33, 0.57]; P<0.00001), severe respiratory illness (RR, 0.29 [0.19, 0.44]; P<0.00001), and hospitalizations (RR, 0.40 [0.24, 0.67]; P=0.0005). RSVpreF vaccination was associated with a higher incidence of preterm delivery (RR, 1.24 [1.08, 1.44]; P=0.003). No significant difference in neonatal deaths was observed (RR, 1.42 [0.70, 2.89]; P=0.34). In conclusion, RSVpreF vaccination results in systemic adverse events and an increase in preterm delivery. Vaccination appears to have acceptable short-term newborn safety, but is not related to a significant decrease in neonatal death.
Abstract
In May 2023, the United States Food and Drug Administration approved a Pfizer©-sponsored (Pfizer, New York, NY, USA) bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) RSV vaccine (AbrysvoTM [Pfizer]) for use during pregnancy to prevent neonatal/infant RSV infection. In February of 2022, trials sponsored by GSK© (Brentford, England, UK) on a similar RSVpreF vaccine were halted because of the identification of a safety signal related to preterm births. As these vaccines use identical pre-fusion F-protein technology, we sought to synthesize the existing data on their effectiveness and safety. We identified all randomized controlled trials and used RevMan 5.4.1 (The Cochrane Collaboration, England, UK) to perform the analysis with 95% confidence intervals and risk ratios (RRs). We found many maternal side effects were more prevalent in the RSVpreF group, with more local reactions, blood disorders, fatigue, joint pain, cardiac disorders, headache, fever, gastrointestinal disorders and pregnancy complications. The vaccinated group demonstrated significant reductions in RSV-lower respiratory tract cases (RR, 0.44 [0.33, 0.57]; P<0.00001), severe respiratory illness (RR, 0.29 [0.19, 0.44]; P<0.00001), and hospitalizations (RR, 0.40 [0.24, 0.67]; P=0.0005). RSVpreF vaccination was associated with a higher incidence of preterm delivery (RR, 1.24 [1.08, 1.44]; P=0.003). No significant difference in neonatal deaths was observed (RR, 1.42 [0.70, 2.89]; P=0.34). In conclusion, RSVpreF vaccination results in systemic adverse events and an increase in preterm delivery. Vaccination appears to have acceptable short-term newborn safety, but is not related to a significant decrease in neonatal death.
참고문헌 (33)
- "Respiratory syncytial virus infection in children" (2013)[URL]
- "Respiratory syncytial virus infection" (2023)[URL]
- Matias G, "Estimates of hospitalization attributable to influenza and RSV in the US during 1997-2009, by age and risk status", BMC Public Health, 17, pp.271~ (2017)
- Shi T, "Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015 : a systematic review and modelling study", Lancet, 390, pp.946~958 (2017)
- Scheltema NM, "Global respiratory syncytial virus-associated mortality in young children(RSV GOLD) : a retrospective case series", Lancet Glob Health, 5, pp.e984~e991 (2017)
- Jain S, "Community-acquired pneumonia requiring hospitalization among U. S. children", N Engl J Med, 372, pp.835~845 (2015)
- Holman RC, "Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population", Pediatrics, 114, pp.e437~e444 (2004)
- Noble M, "Respiratory syncytial virus-associated hospitalisation in children aged ≤5 years : a scoping review of literature from 2009 to 2021", ERJ Open Res, 8, pp.00593-2021~ (2022)
- Valipour M, "Determination of maternal risk factors of preterm delivery : adjusted for sparse data bias; results from a population-based case-control study in Iran", Obstet Gynecol Sci, 63, pp.117~125 (2020)
- Lukacs NW, "Harnessing cellular immunity for vaccination against respiratory viruses", Vaccines(Basel), 8, pp.783~ (2020)
- Willemsen JE, "Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries : a mathematical modeling study", Vaccine X, 15, pp.100379~ (2023)
- Palmeira P, "IgG placental transfer in healthy and pathological pregnancies", Clin Dev Immunol, 2012, pp.985646~ (2012)
- Dudas RA, "Respiratory syncytial virus vaccines", Clin Microbiol Rev, 11, pp.430~439 (1998)
- Lure AC, "Does prefusion F protein-based respiratory syncytial virus immunization in pregnancy safely promote transplacental transfer of neutralizing antibodies?", J Perinatol, 44, pp.142~145 (2024)
- McLellan JS, "Structure and function of respiratory syncytial virus surface glycoproteins", Curr Top Microbiol Immunol, 372, pp.83~104 (2013)
- Andreano E, "The respiratory syncytial virus(RSV)prefusion F-protein functional antibody repertoire in adult healthy donors", EMBO Mol Med, 13, pp.e14035~ (2021)
- Borghesi J, "Immunoglobulin transport during gestation in domestic animals and humans–a review", Open J Anim Sci, 4, pp.323~ (2014)
- "A phase III, double-blind study to assess safety and efficacy of an RSV maternal unadjuvanted vaccine, in pregnant women and infants born to vaccinated mothers (GRACE)" (2024)[URL]
- Boytchev H, "Maternal RSV vaccine : further analysis is urged on preterm births", BMJ, 381, pp.1021~ (2023)
- Simões EAF, "Prefusion F protein-based respiratory syncytial virus immunization in pregnancy", N Engl J Med, 386, pp.1615~1626 (2022)
- Kampmann B, "Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants", N Engl J Med, 388, pp.1451~1464 (2023)
- Dieussaert I, "RSV prefusion F protein-based maternal vaccine-preterm birth and other outcomes", N Engl J Med, 390, pp.1009~1021 (2024)
- Chirikov VV, "Economic-burden trajectories in commercially insured US infants with respiratory syncytial virus infection", J Infect Dis, 221, pp.1244~1255 (2020)
- Li Y, "Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019 : a systematic analysis", Lancet, 399, pp.2047~2064 (2022)
- Esposito S, "RSV prevention in all infants : which is the most preferable strategy?", Front Immunol, 13, pp.880368~ (2022)
- Simões EAF, "Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants", Clin Infect Dis, 73, pp.e4400~e4408 (2021)
- Melgar M, "Use of respiratory syncytial virus vaccines in older adults : recommendations of the advisory committee on immunization practices-United States, 2023", MMWR Morb Mortal Wkly Rep, 72, pp.793~801 (2023)
- Krarup A, "A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism", Nat Commun, 6, pp.8143~ (2015)
- Graham BS, "Vaccine development for respiratory syncytial virus", Curr Opin Virol, 23, pp.107~112 (2017)
- McLellan JS, "Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody", Science, 340, pp.1113~1117 (2013)
- Walsh EE, "Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults", N Engl J Med, 388, pp.1465~1477 (2023)
- Falsey AR, "Phase 1", 2 randomized study of the immunogenicity, safety, and tolerability of a respiratory syncytial virus prefusion F vaccine in adults with concomitant inactivated influenza vaccine, 2022, pp.225, 2056~2066
- Schmoele-Thoma B, "Vaccine efficacy in adults in a respiratory syncytial virus challenge study", N Engl J Med, 386, pp.2377~2386 (2022)